Tuan Zea Tan

Research interests

Publications

• Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition

  Journal of Hematology & Oncology · 2025 · 10.1186/s13045-024-01634-6

• Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis

  Cancers · 2021 · 10.3390/cancers13081882

• Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity

  EMBO Molecular Medicine · 2020 · 10.15252/emmm.201911908

• Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective

  Cancers · 2020 · 10.3390/cancers12010238

• Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

  Clinical Cancer Research · 2020 · 10.1158/1078-0432.ccr-20-2077

• The role of GRHL2 and epigenetic remodeling in epithelial–mesenchymal plasticity in ovarian cancer cells

  Communications Biology · 2019 · 10.1038/s42003-019-0506-3

• Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors

  European Urology · 2018 · 10.1016/j.eururo.2018.08.027

• Dual role of autophagy in hallmarks of cancer

  Oncogene · 2017 · https://doi.org/10.1038/s41388-017-0046-6

• The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200

  OncoImmunology · 2017 · 10.1080/2162402x.2016.1263412

• Molecular characterization of breast cancer CTCs associated with brain metastasis

  Nature Communications · 2017 · 10.1038/s41467-017-00196-1

• The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype–specific therapeutic target for ovarian cancer

  Science Signaling · 2016 · 10.1126/scisignal.aaf8175

• GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification

  Scientific Reports · 2016 · 10.1038/srep19943

• Wanted DEAD/H or Alive: Helicases Winding Up in Cancers

  JNCI Journal of the National Cancer Institute · 2016 · 10.1093/jnci/djw278

• TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex

  Scientific Reports · 2016 · 10.1038/srep27903

• A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets

  Cancer Letters · 2016 · 10.1016/j.canlet.2016.09.001

• Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy

  Oncotarget · 2015 · 10.18632/oncotarget.3903

• Lgr5 marks stem/progenitor cells in ovary and tubal epithelia

  Nature Cell Biology · 2014 · 10.1038/ncb3000

• FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway

  Cell Death and Disease · 2014 · 10.1038/cddis.2014.302

• Epithelial‐mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients

  EMBO Molecular Medicine · 2014 · 10.15252/emmm.201404208

• DEAD-box helicase DP103 defines metastatic potential of human breast cancers

  Journal of Clinical Investigation · 2014 · 10.1172/jci73451

• Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer

  Oncogene · 2014 · 10.1038/onc.2014.136

• Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer

  EMBO Molecular Medicine · 2013 · https://doi.org/10.1002/emmm.201201823

• Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer

  EMBO Molecular Medicine · 2013 · https://doi.org/10.1002/emmm.201201823

• Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis

  Cancer Research · 2013 · 10.1158/0008-5472.can-12-2432

• An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)

  Cell Death and Disease · 2013 · 10.1038/cddis.2013.442

Current projects

No projects listed.